COVID-19 in a group of children with asthma: presentation, severity, and outcome.

IF 1.4 Q4 IMMUNOLOGY American journal of clinical and experimental immunology Pub Date : 2022-01-01
Zeineb A El-Sayed, Rasha H El-Owaidy, Waleed N Harb, Ghada A Shousha
{"title":"COVID-19 in a group of children with asthma: presentation, severity, and outcome.","authors":"Zeineb A El-Sayed,&nbsp;Rasha H El-Owaidy,&nbsp;Waleed N Harb,&nbsp;Ghada A Shousha","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are insufficient data concerning COVID-19 severity among asthmatic children.</p><p><strong>Aim: </strong>to evaluate the impact of asthma on COVID-19 severity and outcome.</p><p><strong>Patients and methods: </strong>We carried out an observational study that comprised 2 matched groups of children with confirmed/probable COVID-19: 30 with and 32 without asthma aged 6-18 years, who were enrolled consecutively from Children's Hospital, Ain Shams University, Egypt. COVID-19 clinical presentations, laboratory and radiological abnormalities, severity and outcome were compared between the 2 groups. Asthma severity and control were assessed based on GINA 2020.</p><p><strong>Results: </strong>The asthmatic COVID-19 children were 9 boys and 21 girls, with median age 9 years, IQR: 8-12 years. The non-asthmatic COVID-19 group included 18 males and 14 females with median age 9.5 years, IQR: 7-12.5 years. Clinical manifestations of COVID-19 were comparable among the 2 groups, except for wheezes which were more frequently encountered as a COVID-19 manifestation among the asthmatics (p=0.001). Multisystem inflammatory syndrome (MIS-c) was diagnosed in one asthmatic and 3 non-asthmatic patients. The asthmatic group had higher frequency of serum ferritin, LDH and D-dimer elevations compared to the non-asthmatic peers (<i>p</i> values 0.014, 0.001, and 0.015 respectively). Based on CO-RAD classification, 70% of the asthmatic patients had CO-RAD score of 5 versus 6.3 % among the non-asthmatic group with significant differences between the 2 groups in their CO-RAD scores (P=0.002). COVID-19 severity was comparable among the studied groups (P=0.775), as well as COVID-19 outcome and duration of hospital stay (<i>p</i> values 0.999, and 0.655, respectively).</p><p><strong>Conclusion: </strong>From our limited sample sized study, childhood asthma did not pose a significant impact on COVID-19 severity and outcome. Further longitudinal studies are warranted to validate our conclusion and investigate the relation of COVID-19 severity and outcome to allergen immunotherapy and the use of biologicals for asthma treatment.</p>","PeriodicalId":72163,"journal":{"name":"American journal of clinical and experimental immunology","volume":null,"pages":null},"PeriodicalIF":1.4000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9845840/pdf/ajcei0011-0092.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of clinical and experimental immunology","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: There are insufficient data concerning COVID-19 severity among asthmatic children.

Aim: to evaluate the impact of asthma on COVID-19 severity and outcome.

Patients and methods: We carried out an observational study that comprised 2 matched groups of children with confirmed/probable COVID-19: 30 with and 32 without asthma aged 6-18 years, who were enrolled consecutively from Children's Hospital, Ain Shams University, Egypt. COVID-19 clinical presentations, laboratory and radiological abnormalities, severity and outcome were compared between the 2 groups. Asthma severity and control were assessed based on GINA 2020.

Results: The asthmatic COVID-19 children were 9 boys and 21 girls, with median age 9 years, IQR: 8-12 years. The non-asthmatic COVID-19 group included 18 males and 14 females with median age 9.5 years, IQR: 7-12.5 years. Clinical manifestations of COVID-19 were comparable among the 2 groups, except for wheezes which were more frequently encountered as a COVID-19 manifestation among the asthmatics (p=0.001). Multisystem inflammatory syndrome (MIS-c) was diagnosed in one asthmatic and 3 non-asthmatic patients. The asthmatic group had higher frequency of serum ferritin, LDH and D-dimer elevations compared to the non-asthmatic peers (p values 0.014, 0.001, and 0.015 respectively). Based on CO-RAD classification, 70% of the asthmatic patients had CO-RAD score of 5 versus 6.3 % among the non-asthmatic group with significant differences between the 2 groups in their CO-RAD scores (P=0.002). COVID-19 severity was comparable among the studied groups (P=0.775), as well as COVID-19 outcome and duration of hospital stay (p values 0.999, and 0.655, respectively).

Conclusion: From our limited sample sized study, childhood asthma did not pose a significant impact on COVID-19 severity and outcome. Further longitudinal studies are warranted to validate our conclusion and investigate the relation of COVID-19 severity and outcome to allergen immunotherapy and the use of biologicals for asthma treatment.

分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
一组哮喘儿童的COVID-19:表现、严重程度和结果
背景:关于哮喘儿童COVID-19严重程度的数据不足。目的:评价哮喘对COVID-19严重程度和转归的影响。患者和方法:我们开展了一项观察性研究,包括两组匹配的确诊/可能患有COVID-19的儿童:30名患有哮喘和32名未患有哮喘的6-18岁儿童,他们连续从埃及艾因沙姆斯大学儿童医院入组。比较两组患者新冠肺炎的临床表现、实验室和影像学异常、严重程度和预后。根据GINA 2020评估哮喘严重程度和控制情况。结果:新冠肺炎哮喘患儿中,男童9例,女童21例,中位年龄9岁,IQR 8 ~ 12岁。非哮喘性COVID-19组男性18例,女性14例,中位年龄9.5岁,IQR 7 ~ 12.5岁。两组患者COVID-19的临床表现具有可比性,但哮喘患者更常出现喘息症状(p=0.001)。1例哮喘患者和3例非哮喘患者诊断为多系统炎症综合征(MIS-c)。哮喘组血清铁蛋白、LDH和d -二聚体的升高频率高于非哮喘组(p值分别为0.014、0.001和0.015)。根据CO-RAD分级,70%的哮喘患者的CO-RAD评分为5分,而非哮喘组的CO-RAD评分为6.3%,两组患者的CO-RAD评分差异有统计学意义(P=0.002)。各组间COVID-19严重程度具有可比性(P=0.775), COVID-19结局和住院时间具有可比性(P值分别为0.999和0.655)。结论:从我们有限的样本量研究中,儿童哮喘对COVID-19的严重程度和结局没有显著影响。需要进一步的纵向研究来验证我们的结论,并调查COVID-19严重程度和结果与过敏原免疫治疗和使用生物制剂治疗哮喘的关系。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Advance in the mechanism and clinical research of myalgia in long COVID. Characterization of tumor suppressors and oncogenes evaluated from TCGA cancers. Clinical utility of multi-row spiral CT in diagnosing hepatic nodular lesions, gastric cancer, and Crohn's disease: a comprehensive meta-analysis. Effectiveness study of surface electromyography combined with spine 3D data system to evaluate scoliosis. The relationship between metabolites and gout: a Mendelian randomization study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1